Efficacy and safety in tirzepatide‐treated Korean adults with type 2 diabetes—A post hoc analysis of SURPASS ‐ AP ‐combo and SURPASS ‐3
An erratum to this article was published (Diabetes Obes Metab, May 2026 ↗)
Authors' conclusion
Consistent with the overall results of the SURPASS-AP-Combo and SURPASS-3 trials, this post hoc subgroup analysis found clinically meaningful reductions in HbA1c and body weight after treatment periods of 40 to 52 weeks in Koreans with T2D treated with tirzepatide.
Study context
- Population
- Korean adults with T2D in SURPASS-AP-Combo (79 of 687 tirzepatide recipients) and SURPASS-3 (27 of 1079 tirzepatide recipients)79 and 27 Korean
- Comparison
- Tirzepatide 5, 10 or 15 mg in Korean participants
Methodological detailsmulticentre, open-label, parallel-group, phase 3
- Multicentre
- Open-label
- Parallel-group
- Phase 3
Primary result
As reported in the abstract
Least squares mean (LSM) HbA1c reduction from baseline
2.75% to 3.25%
HbA1c targets <7.0% and ≤6.5% achieved
84.6% to 100%
LSM body weight reduction from baseline
−6.8% to −10.9%
Composite: HbA1c ≤6.5% without weight gain or clinically significant documented symptomatic or severe hypoglycaemia
69.2% to 85.2%
Further findings
Korean participants, SURPASS-3 · week 52
- Findings were similar in Korean participants of SURPASS-3
Safety
- Safety profile in Korean participants generally consistent with overall SURPASS-AP-Combo and SURPASS-3 populations
Original publication
Composed by AI from the published abstract and checked against it. How Briefs are made →